ANL (Adlai Nortye) Common Stock: $0.01 Mil (As of Dec. 2025)


What is Adlai Nortye Common Stock?

Adlai Nortye ANL +15.07% Common Stock is $0.01 Mil as of Dec. 2025. The stock has 7 warning signs investors should review.

Adlai Nortye's quarterly common stock stayed the same from Dec. 2024 ($0.01 Mil) to Jun. 2025 ($0.01 Mil) but then increased from Jun. 2025 ($0.01 Mil) to Dec. 2025 ($0.01 Mil).

Adlai Nortye's annual common stock stayed the same from Dec. 2023 ($0.01 Mil) to Dec. 2024 ($0.01 Mil) but then increased from Dec. 2024 ($0.01 Mil) to Dec. 2025 ($0.01 Mil).

Adlai Nortye Common Stock Historical Data

* Premium members only.

The historical data trend for Adlai Nortye's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adlai Nortye Common Stock Chart

Adlai Nortye Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Common Stock
0.00 0.00 0.01 0.01 0.01

Adlai Nortye Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Common Stock Get a 7-Day Free Trial Premium Member Only 0.01 0.01 0.01 0.01 0.01

Adlai Nortye Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frequently Asked Questions Learn more about Common Stock →
What does a Common Stock of $0.01 Mil mean?
Adlai Nortye (ANL) has a Common Stock of $0.01 Mil as of Dec. 2025. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Adlai Nortye and its competitors.
Is Adlai Nortye's Common Stock too high?
Adlai Nortye's current Common Stock is $0.01 Mil.
How does Adlai Nortye's Common Stock compare to OMER and PRME?
Adlai Nortye's Common Stock of $0.01 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Biotechnology company?
A good Common Stock depends on the Biotechnology industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Adlai Nortye and its competitors. Adlai Nortye's current Common Stock is $0.01 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adlai Nortye stock overvalued right now?
Adlai Nortye (ANL) has a current Common Stock of $0.01 Mil. The current Common Stock is $0.01 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For Adlai Nortye (ANL), the current Common Stock is $0.01 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Adlai Nortye Business Description

Other Exchanges N2U0:Germany
Address 685 US Highway 1, New Jersey Biotechnology Development Center, 2nd Floor, North Brunswick, NJ, USA, 08902
Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.